-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tocilizumab, a monoclonal antibody that targets mesothetin-6 receptors, is thought to may reduce severe COVID-19-related cytokine storm syndrome.
study was conducted to study the correlation between hospitalization-related mortality in patients with TOcilizumab exposure and life-supporting COVID-19 dependent on ICU.
the study was a retrospective observational queue study conducted in 13 hospitals in the United States.
included in patients with ICU support who have been diagnosed with COVID-19 infection at the age of 18.
forward-looking data from the observation database, comparing the prognosis of patients who received tocilizumab with those who did not.
end point of the disease is hospitalization-related mortality.
1 March-22 April 2020, a total of 764 COVID-19 patients required ICU support, of whom 210 (27 per cent) received tocilizumab treatment.
factors associated with whether or not to receive tocilizumab treatment were the patient's age, sex, kidney function and location of treatment.
630 patients were included in the preference score match, of whom 210 were treated with tocilizumab and 420 were not treated with tocilizumab.
358 (57 per cent) of the 630 patients in the united States died, including 102 (49 per cent) of those treated with tocilizumab and 256 (61 per cent) who were not treated with tocilizumab.
, the medium survival period for patients treated with tocilizumab and those not treated with tocilizumab was not reached and 19 days, respectively, from the start of the drug.
there was a correlation between tocilizumab treatment and a reduction in hospital-related mortality in the main multivariable Cox regression analysis with a tendency to match.
a similar correlation was found in subgroups that required device breath support and a basic C-reactive protein of 15 mg/dL.
: In this observational study, the mortality rate of patients receiving tocilizum treatment coVID-19, which required ICU support, decreased.
results of a randomized controlled trial that is currently under way are about to be released.
.
